Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

pembrolizumab 4aldesleukin 3Cisplatin 3lenvatinib 2Surveys and Questionnaires 2Specimen Handling 2Paclitaxel 2Nivolumab 2Methods 2Magnetic Resonance Spectroscopy 2Adoptive Transfer 2zimberelimab 1trastuzumab deruxtecan 1tivozanib 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1entinostat 1dostarlimab 1cemiplimab 1bintrafusp alfa protein, human 1belzutifan 1atezolizumab 1Therapeutic Touch 1Taxes 1Standard of Care 1Sonazoid 1Respiratory Function Tests 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Innovar × 1 year × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡